"her2 positive proportion" trang 1 - tải miễn phí từ tailieunhanh
Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: Study protocol of a randomized controlled trial

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: Study protocol of a randomized controlled trial
6    60    1
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis
7    25    1
Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: Results of a randomized study - SAKK 22/99

Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: Results of a randomized study - SAKK 22/99
9    49    1
Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples

Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples
9    75    1
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
10    18    1
Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results
7    55    1
The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients
10    65    1
High score of LDH plus dNLR predicts poor survival in patients with HER2- positive advanced breast cancer treated with trastuzumab emtansine

High score of LDH plus dNLR predicts poor survival in patients with HER2- positive advanced breast cancer treated with trastuzumab emtansine
13    36    3
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
9    18    1
Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients

Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients
8    51    1
A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
7    58    1
Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study

Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study
11    73    1
Histone demethylase GASC1 - a potential prognostic and predictive marker in invasive breast cancer

Histone demethylase GASC1 - a potential prognostic and predictive marker in invasive breast cancer
15    63    1
Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: A retrospective single-center study

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: A retrospective single-center study
7    56    3
Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: A multicenter real-world study in the northwest of China

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: A multicenter real-world study in the northwest of China
13    6    1
Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2- negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: A propensity score matching study based on SEER database

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2- negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: A propensity score matching study based on SEER database
11    52    1
Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy
9    90    0
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review
8    84    1
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2 - positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2 - positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
10    49    1
Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2- positive gastric cancer

Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2- positive gastric cancer
10    47    1